The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer

Borgmann, Kerstin; Raabe, Annette; Reuther, Sebastian; Szymczak, Silke; Schlomm, Thorsten; Isbarn, Hendrik; Gomolka, Maria; Busjahn, Andreas; Bonin, Michael; Ziegler, Andreas; Dikomey, Ekkehard

doi:10.1016/j.radonc.2010.04.018

« Previous Next »Radiotherapy & Oncology
Volume 96, Issue 1 , Pages 19-24, July 2010

The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer

Kerstin Borgmann
- Laboratory of Radiobiology & Experimental Radiooncology, University Medical Center Hamburg-Eppendorf, Germany
Annette Raabe
- Laboratory of Radiobiology & Experimental Radiooncology, University Medical Center Hamburg-Eppendorf, Germany
Sebastian Reuther
- Laboratory of Radiobiology & Experimental Radiooncology, University Medical Center Hamburg-Eppendorf, Germany
Silke Szymczak
- Institute of Medical Biometry and Statistics, University at Lübeck, University Hospital Schleswig-Holstein, Germany
Thorsten Schlomm
- Department of Urology, University Medical Center Hamburg-Eppendorf, Germany
Hendrik Isbarn
- Department of Urology, University Medical Center Hamburg-Eppendorf, Germany
Maria Gomolka
- Department of Radiation Protection and Health, Federal Office for Radiation Protection, Oberschleissheim, Germany
Andreas Busjahn
- HealthTwiSt GmbH, Berlin, Germany
Michael Bonin
- Department of Medical Genetics, University of Tübingen, Germany
Andreas Ziegler
- Institute of Medical Biometry and Statistics, University at Lübeck, University Hospital Schleswig-Holstein, Germany
Ekkehard Dikomey
- Laboratory of Radiobiology & Experimental Radiooncology, University Medical Center Hamburg-Eppendorf, Germany
- Corresponding author. Address: Laboratory of Radiobiology & Experimental Radiooncology, Campus Forschung, N27, Martinistraße 52, D-20246 Hamburg, Germany.

Received 7 December 2009; received in revised form 9 April 2010; accepted 12 April 2010. published online 10 May 2010.

Abstract

Purpose

Comparing the chromosomal radiosensitivity of prostate cancer patients with that of healthy donors.

Materials and methods

The study was performed on 81 prostate cancer patients characterised by a clinical stage of predominantly pT2c or pT3a and a median age of 67years. As healthy donors 60 male monozygotic twin pairs were recruited with a median age of 28years. Chromosomal radiosensitivity was measured using both G0- and G2-assay.

Results

No difference between healthy donors and prostate cancer patients was detected concerning G0-radiosensitivity, since medians were similar (Hodges–Lehmann estimate: −0.05, 95% CI: −0.18–0.08, p=0.4167). However, a pronounced difference was determined for G2-radiosensitivity with prostate cancer patients showing a significantly higher sensitivity compared to healthy donors (Hodges–Lehmann estimate: −0.41, 95% CI: −0.53 to −0.30, p=1.75⁻⁹). Using the 90% quantile of G2-radiosensitivity in healthy donors as a threshold for discrimination the fraction of prostate cancer patients with elevated radiosensitivity increased to 49%.